VERTEX PHARMACEUTICALS INC / MA Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $148.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $600.00K.
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $148.20M, a 2750.00% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $200.00K, a 99.04% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $305.70M, a 62.02% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $311.00M, a 72.25% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $1.12B, a 46604.17% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.40M, a 95.90% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $58.60M, a 61.43% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $148.80M 10-Q · filed 2026-08-04 | $149.00M derived: sum of 3 quarters · filed 2026-08-04 | $454.70M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | $148.20M 10-Q · filed 2026-05-05 | $148.40M derived: sum of 2 quarters · filed 2026-05-05 | $454.10M derived: sum of 3 quarters · filed 2026-05-05 | $454.00M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $305.90M derived: sum of 2 quarters · filed 2026-02-13 | $305.80M derived: sum of 3 quarters · filed 2026-08-04 | $311.00M 10-K · filed 2026-02-13 | |
| 2025-09-30 | $305.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $305.60M derived: sum of 2 quarters · filed 2026-08-04 | $310.80M 10-Q · filed 2025-11-04 | $331.70M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.10M 10-Q · filed 2026-08-04 | $26.00M derived: sum of 3 quarters · filed 2026-08-04 | $831.00M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | $5.20M 10-Q · filed 2026-05-05 | $26.10M derived: sum of 2 quarters · filed 2026-05-05 | $831.10M derived: sum of 3 quarters · filed 2026-05-05 | $1.09B derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $20.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $825.90M derived: sum of 2 quarters · filed 2026-02-13 | $1.09B derived: sum of 3 quarters · filed 2026-02-13 | $1.12B 10-K · filed 2026-02-13 | |
| 2024-09-30 | $805.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.07B derived: sum of 2 quarters · filed 2025-11-04 | $1.10B 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $262.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $295.00M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $32.30M 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | $2.40M 10-K · filed 2026-02-13 | ||||
| 2022-12-31 | $58.60M 10-K · filed 2025-02-13 | ||||
| 2021-12-31 | $36.30M 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $293.60M 10-K · filed 2023-02-10 | $293.60M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $28.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $34.60M derived: sum of 2 quarters · filed 2022-02-09 | $34.60M derived: sum of 3 quarters · filed 2022-02-09 | $34.60M 10-K · filed 2022-02-09 | $34.60M 10-K · filed 2020-02-13 |
| 2019-09-30 | $6.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $6.08M derived: sum of 2 quarters · filed 2019-10-31 | $6.08M 10-Q · filed 2019-10-31 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |